RAPAMUNE® is the first and only kidney transplant therapeutic with dosing recommendations specifically for the treatment of high immunologic risk renal transplant recipients.
In high immunologic risk patients, it is recommended that a RAPAMUNE-based regimen be used in combination with cyclosporine (CsA) and corticosteroids for the first year following transplantation.
Now, with the newly approved dosing recommendation, RAPAMUNE® can be used in combination with antibody induction therapy in high immunologic risk kidney transplant patients.
This particular patient population have a greater likelihood of developing acute rejection than low to moderate risk kidney transplant recipients.
High immunologic risk patients are defined as transplant recipients who are Black; and/or repeat renal transplant recipients who lost a previous kidney transplant for immunologic reasons; and/or patients with high-panel reactive antibodies (PRA). For patients with high PRA, it is more difficult to find a compatible organ donor.
RAPAMUNE® (sirolimus) belongs to a novel class of immunosuppressant agents called mammalian target of rapamycin (mTOR) inhibitors, a key regulatory enzyme involved in cell growth and survival.
Wyeth Pharmaceuticals, Inc. (10944776) is a division of Wyeth (NYSE: WYE).
Source: Wyeth News
[Photo Credit: Wyeth Pharmaceuticals]
.jpg)
Comment Preview